- Home
- THG vs NUVL Comparison
THG vs NUVL Comparison
Compare THG & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THG
- NUVL
- Stock Information
- Founded
- THG 1852
- NUVL 2017
- Country
- THG United States
- NUVL United States
- Employees
- THG N/A
- NUVL N/A
- Industry
- THG Property-Casualty Insurers
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- THG Finance
- NUVL Health Care
- Exchange
- THG Nasdaq
- NUVL Nasdaq
- Market Cap
- THG 5.8B
- NUVL 5.6B
- IPO Year
- THG 1995
- NUVL 2021
- Fundamental
- Price
- THG $166.74
- NUVL $71.23
- Analyst Decision
- THG Buy
- NUVL Strong Buy
- Analyst Count
- THG 9
- NUVL 8
- Target Price
- THG $179.00
- NUVL $115.50
- AVG Volume (30 Days)
- THG 266.8K
- NUVL 660.5K
- Earning Date
- THG 04-30-2025
- NUVL 05-08-2025
- Dividend Yield
- THG 2.16%
- NUVL N/A
- EPS Growth
- THG 167.70
- NUVL N/A
- EPS
- THG 12.02
- NUVL N/A
- Revenue
- THG $6,289,500,000.00
- NUVL N/A
- Revenue This Year
- THG $5.97
- NUVL N/A
- Revenue Next Year
- THG $5.93
- NUVL N/A
- P/E Ratio
- THG $13.88
- NUVL N/A
- Revenue Growth
- THG 3.09
- NUVL N/A
- 52 Week Low
- THG $119.66
- NUVL $55.54
- 52 Week High
- THG $176.16
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- THG 53.84
- NUVL 51.04
- Support Level
- THG $165.49
- NUVL $63.56
- Resistance Level
- THG $171.09
- NUVL $78.97
- Average True Range (ATR)
- THG 3.59
- NUVL 3.30
- MACD
- THG 0.53
- NUVL -0.20
- Stochastic Oscillator
- THG 63.24
- NUVL 59.65
About THG Hanover Insurance Group Inc
The Hanover Insurance Group Inc is a holding company whose primary business is offering property and casualty insurance products and services. The company markets itself through independent agents and brokers in the United States while conducting business internationally through a wholly owned subsidiary, Chaucer Holdings Limited, domiciled in the United Kingdom. The company conducts business operations through three operating segments: Commercial Lines, Personal Lines, and Other. The company operates an investment portfolio that is exposed to fixed-income securities.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.